Covina, CA, United States
Covina, CA, United States

Time filter

Source Type

"The practice of helping babies by providing stem cells at birth has been around for a long time; it makes sense for the sickest infants," said Anup Katheria, MD, director of the Neonatal Research Institute. "We're focused on producing evidence that shows the benefits. We think this could become the foundation for practice-changing birthing techniques, transforming outcomes for the most critical of newborns nationwide." As a California-based public/private cord blood banking company and with a strong research focus, StemCyte stands ready to help efficiently and effectively to support the partnership with Sharp HealthCare to educate expecting parents of their options, to ensure the information is delivered accurately and consistently, and to collect the cells in cord blood and process and store them with the highest quality standards in the industry. "We are excited to work with the Sharp Mary Birch Neonatal Research Institute, and we are looking forward to maximizing the capacity for cord-blood banking. Residents of California and people around the world will benefit from the research and increased availability of umbilical cord blood stem cell transplant units." said Jonas C. Wang, Ph.D., CEO/ Chairman of StemCyte Group. About StemCyte StemCyte's rich history started with a mission of being dedicated to helping the world's physicians save more lives by providing high quality, safe and effective stem cell transplantation and therapy to all patients in need. Located in the US, India and Taiwan, StemCyte has supplied over 2100 cord blood products for over 40 life-threatening diseases to over 300 leading worldwide transplant centers.  StemCyte is actively involved in the development of stem cell therapies. StemCyte was the first to donate umbilical cord blood units (UCB) to Dr. Jaing of Chung Gung Memorial Hospital for his clinical trial to use UCB to treat and cure Beta Thalassemia.  More excitingly is the work and accomplishments of Prof Wise Young, MD, PhD.  Prof. Young has completed Phase II clinical trials on patients with chronic spinal cord injury with UCB and the results are extremely encouraging. StemCyte is chosen by the US Department of Health and Human Services to help establishing a public National Cord Blood Inventory. Its headquarters are located in Baldwin Park, CA.  To learn more visit www.StemCyte.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/stemcyte-renewed-strategic-partnership-with-the-neonatal-research-institute-at-sharp-mary-birch-hospital-for-women--newborns-300464844.html


Patent
StemCyte | Date: 2010-04-16

This invention provides methods for supplying a therapy for individuals exposed to radiation following a nuclear event, through the prospective establishment of an undesignated allogeneic stem cell bank with prospective HLA typing of healthy potential recipients.


Patent
StemCyte | Date: 2014-04-18

Disclosed are recombinant stem cells that are resistant to HIV infection. Also disclosed are their uses in treating AIDS.


Patent
StemCyte | Date: 2010-10-20

This invention provides methods for supplying a therapy for individuals exposed to radiation following a nuclear event, through the prospective establishment of an undesignated allogeneic stem cell bank with prospective HLA typing of healthy potential recipients.


Patent
StemCyte | Date: 2010-04-06

Disclosed are recombinant stem cells that are resistant to HIV infection. Also disclosed are their uses in treating AIDS.


Patent
StemCyte | Date: 2010-05-21

Disclosed are methods for conditioning stems cells and using the conditioned stems cells for treating brain tissue damage.


Patent
StemCyte | Date: 2012-02-14

This invention concerns methods of packaging and shipping stem cells. Also disclosed are related package products.


Petz L.,StemCyte
Stem Cells Translational Medicine | Year: 2013

HIV infection has not been cured by antiretroviral drugs or gene therapy, but it has been cured by a hematopoietic cell transplantation (HCT) that was performed for a patient with acute myeloid leukemia and HIV infection using peripheral blood stem cells from an adult donor homozygous for CCR5-Δ32 (CCR5-Δ32/Δ32). HIV has remained undetectable more than 6 years after discontinuation of antiretroviral therapy. However, this approach cannot be readily generalized because of the low prevalence of the CCR5-Δ32 allele and the need for a very close human leukocyte antigen (HLA) match between adult donors and recipients, as when bone marrow or peripheral blood stem cell transplants are performed. In contrast, cord blood (CB) transplants require less stringent HLA matching. CB units are being screened to develop an inventory of cryopreserved homozygous CCR5-Δ32 units available for HCT. One hundred eighty homozygous CCR5-Δ32 units have been identified, and 300 units are projected to provide for white pediatric patients a 73.6% probability of finding an adequately HLA-matched unit with a minimal cell dose of ≥2.5×107 total nucleated cells (TNC) per kilogram and for white adults a 27.9% probability. With a minimal cell dose requirement of ≥1 ×107 TNC per kilogram, the corresponding projected probabilities are 85.6% and 82.1%. CB transplantation does not require as stringent an HLA match between donor and recipient as bone marrow or peripheral blood HCTs, and HCT using cord bloods from donors homozygous for CCR5-Δ32 is, at the present time, the only feasible means of treatment of reasonable numbers of patients who are infected with HIV. © AlphaMed Press 2013.


News Article | November 19, 2016
Site: marketersmedia.com

Wiseguyreports.Com Adds “Stem Cell Banking -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database This report studies sales (consumption) of Stem Cell Banking in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Stem Cell Banking in these regions, from 2011 to 2021 (forecast), like United States China Europe Japan Split by product Types, with sales, revenue, price and gross margin, market share and growth rate of each type, can be divided into Type I Type II Type III Split by applications, this report focuses on sales, market share and growth rate of Stem Cell Banking in each application, can be divided into Application 1 Application 2 Application 3 Global Stem Cell Banking Sales Market Report 2016 1 Stem Cell Banking Overview 1.1 Product Overview and Scope of Stem Cell Banking 1.2 Classification of Stem Cell Banking 1.2.1 Type I 1.2.2 Type II 1.2.3 Type III 1.3 Application of Stem Cell Banking 1.3.1 Application 1 1.3.2 Application 2 1.3.3 Application 3 1.4 Stem Cell Banking Market by Regions 1.4.1 United States Status and Prospect (2011-2021) 1.4.2 China Status and Prospect (2011-2021) 1.4.3 Europe Status and Prospect (2011-2021) 1.4.4 Japan Status and Prospect (2011-2021) 1.5 Global Market Size (Value and Volume) of Stem Cell Banking (2011-2021) 1.5.1 Global Stem Cell Banking Sales and Growth Rate (2011-2021) 1.5.2 Global Stem Cell Banking Revenue and Growth Rate (2011-2021) 7 Global Stem Cell Banking Manufacturers Analysis 7.1 StemCyte (U.S.) 7.1.1 Company Basic Information, Manufacturing Base and Competitors 7.1.2 Stem Cell Banking Product Type, Application and Specification 7.1.2.1 Type I 7.1.2.2 Type II 7.1.3 StemCyte (U.S.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.1.4 Main Business/Business Overview 7.2 Cryo-Cell International (U.S.) 7.2.1 Company Basic Information, Manufacturing Base and Competitors 7.2.2 116 Product Type, Application and Specification 7.2.2.1 Type I 7.2.2.2 Type II 7.2.3 Cryo-Cell International (U.S.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.2.4 Main Business/Business Overview 7.3 ViaCord (U.S.) 7.3.1 Company Basic Information, Manufacturing Base and Competitors 7.3.2 133 Product Type, Application and Specification 7.3.2.1 Type I 7.3.2.2 Type II 7.3.3 ViaCord (U.S.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.3.4 Main Business/Business Overview 7.4 Cord Blood Registry (U.S.) 7.4.1 Company Basic Information, Manufacturing Base and Competitors 7.4.2 Nov Product Type, Application and Specification 7.4.2.1 Type I 7.4.2.2 Type II 7.4.3 Cord Blood Registry (U.S.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.4.4 Main Business/Business Overview 7.5 Smart Cells (U.K.) 7.5.1 Company Basic Information, Manufacturing Base and Competitors 7.5.2 Product Type, Application and Specification 7.5.2.1 Type I 7.5.2.2 Type II 7.5.3 Smart Cells (U.K.) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.5.4 Main Business/Business Overview 7.6 Cryo-Save (Netherlands) 7.6.1 Company Basic Information, Manufacturing Base and Competitors 7.6.2 Million USD Product Type, Application and Specification 7.6.2.1 Type I 7.6.2.2 Type II 7.6.3 Cryo-Save (Netherlands) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.6.4 Main Business/Business Overview 7.7 Cryoviva (India) 7.7.1 Company Basic Information, Manufacturing Base and Competitors 7.7.2 Pharmaceuticals Product Type, Application and Specification 7.7.2.1 Type I 7.7.2.2 Type II 7.7.3 Cryoviva (India) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.7.4 Main Business/Business Overview 7.8 LifeCell (India) 7.8.1 Company Basic Information, Manufacturing Base and Competitors 7.8.2 Product Type, Application and Specification 7.8.2.1 Type I 7.8.2.2 Type II 7.8.3 LifeCell (India) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.8.4 Main Business/Business Overview 7.9 Cordlife (Singapore) 7.9.1 Company Basic Information, Manufacturing Base and Competitors 7.9.2 Product Type, Application and Specification 7.9.2.1 Type I 7.9.2.2 Type II 7.9.3 Cordlife (Singapore) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.9.4 Main Business/Business Overview 7.10 Cordvida (Brazil) 7.10.1 Company Basic Information, Manufacturing Base and Competitors 7.10.2 Product Type, Application and Specification 7.10.2.1 Type I 7.10.2.2 Type II 7.10.3 Cordvida (Brazil) Stem Cell Banking Sales, Revenue, Price and Gross Margin (2011-2016) 7.10.4 Main Business/Business Overview 7.11 Cord Blood Corporation (China) For more information, please visit https://www.wiseguyreports.com/sample-request/749197-global-stem-cell-banking-sales-market-report-2016


News Article | November 8, 2016
Site: www.newsmaker.com.au

MarketStudyReport.com adds “Global Stem Cell Banking Market by Manufacturers, Regions, Type and Application, Forecast to 2021” new report to its research database. The report spread across 113 pages with table and figures in it. Stem Cell Banking refers to the human stem cell transplantation for the purpose, with acquisition, processing, preservation and provides the ability to differentiate stem cell storage bank, has been called the "life bank". Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-stem-cell-banking-market-by-manufacturers-regions-type-and-application-forecast-to-2021/ Scope of the Report: This report focuses on the Stem Cell Banking in Global market, especially in North America, Europe and Asia-Pacific, Latin America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Market Segment by Manufacturers, this report covers CCBC CBR ViaCord Esperite Vcanbio Boyalife LifeCell Crioestaminal RMS Regrow Cordlife Group PBKM FamiCord cells4life Beikebiotech StemCyte Cryo-cell Cellsafe Biotech Group PacifiCord Americord Krio Familycord Cryo Stemcell Stemade Biotech Market Segment by Regions, regional analysis covers North America (USA, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Latin America, Middle East and Africa Market Segment by Type, covers Umbilical Cord Blood Stem Cell Embryonic Stem Cell Adult Stem Cell Other Market Segment by Applications, can be divided into Diseases Therapy Healthcare There are 13 Chapters to deeply display the global Stem Cell Banking market. Chapter 1, to describe Stem Cell Banking Introduction, product scope, market overview, market opportunities, market risk, market driving force; Chapter 2, to analyze the top manufacturers of Stem Cell Banking, with sales, revenue, and price of Stem Cell Banking, in 2015 and 2016; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2015 and 2016; Chapter 4, to show the global market by regions, with sales, revenue and market share of Stem Cell Banking, for each region, from 2011 to 2016; Chapter 5, 6, 7 and 8, to analyze the key regions, with sales, revenue and market share by key countries in these regions; Chapter 9 and 10, to show the market by type and application, with sales market share and growth rate by type, application, from 2011 to 2016; Chapter 11, Stem Cell Banking market forecast, by regions, type and application, with sales and revenue, from 2016 to 2021; Chapter 12 and 13, to describe Stem Cell Banking sales channel, distributors, traders, dealers, appendix and data source. To receive personalized assistance write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150

Loading StemCyte collaborators
Loading StemCyte collaborators